Orion Archives -

Merck & Co has added another clinical-stage drug to its oncology pipeline via a licensing agreement with Finland’s

Merck buys into Orion prostate cancer therapy in $290m deal

https://pharmaphorum.com/news/merck-buys-into-orion-prostate-cancer-therapy-in-290m-deal/

Bayer has filed for approval to extend the use of its prostate cancer therapy Nubeqa as it tries

Chasing rivals, Bayer files Nubeqa for new prostate cancer use

https://pharmaphorum.com/news/chasing-rivals-bayer-files-nubeqa-for-new-prostate-cancer-use/

Could virtual reality tools be effective in helping patients ‘unlearn’ their chronic pain? Professor Christopher Eccleston from the

Virtual reality therapy: The future of chronic pain management?

https://pharmaphorum.com/views-and-analysis/virtual-reality-therapy-the-future-of-chronic-pain-management/

A digital therapeutic aimed at people with chronic lower back pain based on virtual reality (VR) has shown

Trial finds Orion digital therapeutic helps chronic pain sufferers

https://pharmaphorum.com/news/trial-finds-orion-digital-therapeutic-helps-chronic-pain-sufferers/

The FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease

Bayer aims at J&J and Pfizer with new prostate cancer drug

https://pharmaphorum.com/news/bayer-aims-at-jj-and-pfizer-with-new-prostate-cancer-drug/

Bayer and development partner Orion have released detailed results from the trial that will form the backbone of

Bayer/Orion showcase results from prostate cancer challenger

https://pharmaphorum.com/news/bayer-orion-showcase-results-from-prostate-cancer-challenger/

Review of Second Sight’s Orion will now be streamlined.

‘Bionic eye’ receives FDA fast-track review designation

https://pharmaphorum.com/news/bionic-eye-fda-fast-track/

Orion